Dr. Balar on Results of KEYNOTE-052 in Urothelial Cancer

Video

Arjun Balar, MD, director, Genitourinary Medical Oncology Progam, NYU Langone Medical Center, discusses the results from the KEYNOTE-053 trial in cisplatin-ineligible advanced urothelial carcinoma.

Arjun Balar, MD, director, Genitourinary Medical Oncology Progam, NYU Langone Medical Center, discusses the results from the KEYNOTE-052 trial in cisplatin-ineligible advanced urothelial carcinoma.

In this study of 370 patients, 200 mg of pembrolizumab (Keytruda) was administered every 3 weeks. At week 9, imaging was performed and then every 6 weeks for the first year and every 12 weeks beyond that.

The study met its primary end point of overall response rate, which was 27% among patients with a greater than 4-month follow-up. The complete response rate was 6%.

Balar concludes that this study confirms the effectiveness and durability of pembrolizumab in cisplatin-ineligible patients with urothelial carcinoma.

Related Videos
Wenxin (Vincent) Xu, MD,
Wenxin (Vincent) Xu, MD
A panel of 4 experts on bladder cancer
A panel of 4 experts on bladder cancer
Wenxin (Vincent) Xu, MD
Patrick I. Borgen, MD
A panel of 5 experts on renal cell carcinoma
A panel of 5 experts on renal cell carcinoma
Kari Hacker, MD, PhD, NYU Grossman School of Medicine
Janos L. Tanyi, MD, PhD, associate professor, Obstetrics and Gynecology, Hospital of the University of Pennsylvania